Novel therapeutic effects of sesamin on diabetes-induced cardiac dysfunction
Journal
Molecular Medicine Reports
Journal Volume
15
Journal Issue
5
Pages
2949-2956
Date Issued
2017
Author(s)
Thuy, Tran Duong
Phan, Nam Nhut
Wang, Chih-Yang
Yu, Han-Gang
Wang, Shu-Yin
Huang, Pung-Ling
Lin, Yen-Chang
Abstract
Diabetes is a risk factor that increases the occurrence and severity of cardiovascular events. Cardiovascular complications are the leading cause of mortality of 75% of patients with diabetes >40 years old. Sesamin, the bioactive compound extracted from Sesamum indicum, is a natural compound that has diverse benefcial effects on hypoglycemia and reducing cholesterol. The aim of this study is to investigate sesamin effects to diabetes-inducing cardiac hypertrophy. In the present study bioinformatics analysis demonstrated cardiac hypertrophy signaling may be the most important pathway for upregulating genes in sesamin-treated groups. To verify the bioinformatics prediction, sesamin was used as the main bioactive compound to attenuate the impact of diabetes induced by streptozotocin (STZ) on cardiac function in a rat model. The results revealed that oral administration of sesamin for 4 weeks (100 and 200 mg/kg body weight) marginally improved blood glucose levels, body weight and signifcantly ameliorated the effects on heart rate and blood pressure in rats with type 1 diabetes relative to control rats. The QT interval of sesamin was also reduced relative to the control group. The fndings indicated that sesamin has potential cardioprotective effects in the STZ-induced diabetes model. This suggested that this can be used as a novel treatment for patients with diabetes with cardiac dysfunction complication.
Subjects
Cardiac dysfunction; Diabetes; Sesamin
SDGs
Other Subjects
calmodulin binding transcription activator 2; cyclic AMP responsive element binding protein binding protein; E1A associated p300 protein; glucose; heart and neural crest derivatives expressed 1; heart and neural crest derivatives expressed 2; homeobox protein Nkx-2.5; myocyte enhancer factor 2; myocyte enhancer factor 2a; myocyte enhancer factor 2c; myocyte enhancer factor 2d; myosin heavy chain alpha; myosin heavy chain beta; peptides and proteins; sesamin; streptozocin; transcription factor GATA 4; transcription factor NFAT; troponin I; troponin T; unclassified drug; 1,3 dioxolane derivative; lignan; sesamin; streptozocin; animal experiment; animal model; Article; blood pressure measurement; blood sampling; body weight; controlled study; diastolic blood pressure; diet; drug megadose; echocardiography; electrocardiography; glucose blood level; heart function; heart output; heart protection; heart rate measurement; heart tissue; heart ventricle hypertrophy; histology; histopathology; intracellular signaling; low drug dose; male; nonhuman; outcome assessment; protein degradation; protein DNA interaction; protein protein interaction; QT interval; rat; streptozotocin-induced diabetes mellitus; therapy effect; analysis; animal; blood pressure; cardiac muscle; cardiomegaly; chemically induced; complication; diagnostic imaging; drug effects; experimental diabetes mellitus; heart; heart rate; oral drug administration; pathology; physiology; Sprague Dawley rat; Administration, Oral; Animals; Blood Glucose; Blood Pressure; Body Weight; Cardiomegaly; Diabetes Mellitus, Experimental; Dioxoles; Electrocardiography; Heart; Heart Rate; Lignans; Male; Myocardium; Rats; Rats, Sprague-Dawley; Streptozocin
Type
journal article